Please Wait
Applying Filters...
menu
    • menu
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Evonik

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-21

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    An Enquiry

    Menu

    Mizagliflozin

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Vogenx to Present Mizagliflozin Phase 2 Data at ENDO 2025
    Vogenx to Present Mizagliflozin Phase 2 Data at ENDO 2025

    15 Apr 2025

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/vogenx-inc-to-present-phase-2-clinical-data-on-mizagliflozin-at-the-e-1015263

    ACCESSWIRE
    15 Apr 2025
    Share Share
    Vogenx Announces Positive Phase 2 Results For Mizagliflozin In Hypoglycemia
    Vogenx Announces Positive Phase 2 Results For Mizagliflozin In Hypoglycemia

    26 Jun 2024

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=882166&lang=en

    ACCESSWIRE
    26 Jun 2024
    Share Share
    Vogenx Completes Dosing of Last Patient in Ph 2 Study of Mizagliflozin
    Vogenx Completes Dosing of Last Patient in Ph 2 Study of Mizagliflozin

    02 Apr 2024

    // ACCESSWIRE

    https://www.accesswire.com/849173/vogenx-completes-dosing-of-last-patient-in-phase-2-clinical-study-of-mizagliflozin-for-the-treatment-of-post-bariatric-hypoglycemia

    ACCESSWIRE
    02 Apr 2024
    Share Share
    Vogenx Completes Enrollment of Phase 2 Trial of Mizagliflozin
    Vogenx Completes Enrollment of Phase 2 Trial of Mizagliflozin

    15 Feb 2024

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=833986&lang=en

    ACCESSWIRE
    15 Feb 2024
    Share Share